Generic Name and Formulations:
Tacrolimus 0.5mg, 1mg, 5mg; caps.
Astellas Pharma US, Inc.
Indications for PROGRAF:
Organ rejection prophylaxis in patients with allogeneic kidney, liver, and heart transplants, in combination with other immunosuppressants.
Give at least 6hrs after transplantation. If previously on IV infusion, initial oral dose may be given 8–12hrs post infusion. Liver (with corticosteroids only): initially 0.1–0.15mg/kg/day in two divided dose every 12hrs. Concomitant corticosteroid is recommended early post-transplantation. Heart (with azathioprine or MMF): initially 0.075mg/kg/day in two divided doses every 12hrs. Kidney (may be given within 24hrs of transplantation but should be delayed until renal function has recovered): initially 0.2mg/kg/day in two divided doses every 12hrs in combination with azathioprine; or 0.1mg/kg/day in two divided doses every 12hrs in combination with MMF/IL-2 receptor antagonist; black patients may require higher doses. Renal or hepatic impairment: use lowest effective dose (see full labeling). Post-op oliguria: may delay therapy until renal function recovers.
Give at least 6hrs after transplantation. If previously on IV infusion, initial oral dose may be given 8–12hrs post infusion. Kidney: initially 0.3mg/kg/day in two divided doses every 12hrs. Liver: initially 0.15–0.2mg/kg/day in two divided doses every 12hrs. Heart: initially 0.3mg/kg/day (0.1mg/kg/day if cell depleting induction treatment is administered) in two divided doses every 12hrs.
Malignancies. Serious infections.
Increased risk of lymphomas and other malignancies (eg, skin) due to immunosuppression. Avoid sun, UV light. Increased risk of infections (eg, bacterial, viral, fungal, protozoal), including opportunistic infections. Oral forms are not interchangeable with other tacrolimus ext-rel products. Only physicians experienced in immunosuppressive therapy should prescribe Prograf. Risk of new onset diabetes after transplant. Hepatic or renal impairment; monitor and consider dose reduction. Obtain tacrolimus whole blood concentrations, serum creatinine, potassium, and fasting glucose periodically. Monitor and control BP. Avoid in congenital long QT syndrome. CHF, bradyarrhythmias, concomitant antiarrhythmic drugs, or electrolyte disturbances; consider obtaining ECGs and monitor electrolytes periodically. Discontinue or reduce dose if myocardial hypertrophy occurs. Pregnancy, labor & delivery, nursing mothers: see full labeling.
Concomitant sirolimus (in liver/heart transplant), live vaccines: not recommended. Concomitant strong CYP3A4 inhibitors/inducers or substrates: must adjust dosing regimen, closely monitor tacrolimus blood concentrations and for QT prolongation. Avoid grapefruit or grapefruit juice. Caution with potassium-sparing diuretics, ACEIs, ARBs during therapy. Additive nephrotoxicity with cyclosporine (discontinue at least 24hrs prior to initiating the other drug), aminoglycosides, ganciclovir, amphotericin B, cisplatin, NRTIs, protease inhibitors. May be potentiated by calcium channel blockers (eg, diltiazem, nifedipine), antifungals (eg, fluconazole, ketoconazole, voriconazole, posaconazole, itraconazole), macrolides (eg, troleandomycin, clarithromycin, erythromycin), metoclopramide, lansoprazole, omeprazole, chloramphenicol, cimetidine, cyclosporine, danazol, ethinyl estradiol, amiodarone, schisandra sphenanthera extract, protease inhibitors (eg, nelfinavir, telaprevir, boceprevir, ritonavir), nefazodone, magnesium-aluminum-hydroxide. May be antagonized by carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St. Johns Wort, methylprednisolone, prednisone. Caution with mycophenolic acid; reduce dose of these as needed.
Tremor, headache, constipation, diarrhea, nausea, abdominal pain, insomnia, hypertension, renal dysfunction, fever, serious viral infections (eg, CMV, PML, PVAN), leukopenia, anemia, bronchitis, pericardial effusion, UTI, paresthesia, peripheral edema, hypophosphatemia, hyperkalemia, hypomagnesemia, hyperlipidemia, hyperglycemia; nephrotoxicity or neurotoxicity (esp. in high doses), diabetes mellitus, posterior reversible encephalopathy syndrome (consider reduced dose or discontinue), malignancies (eg, lymphomas, skin), post-transplant lymphoproliferative disorder, myocardial hypertrophy, pure red cell aplasia, Torsade de Pointes; IV: anaphylactic reactions (monitor).
Hepatic (CYP3A4); 99% protein bound.
Fecal (primary), renal.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline